Report Highlights

The U.S.'s Role in the Global Rapid Diagnostics Supply Chain

The United States occupies the dual role of the world's largest rapid diagnostics consumer and a critical manufacturing and innovation hub for the sector. U.S.-based production facilities operated by Abbott (Illinois), Quidel (Ohio and California), and Becton Dickinson (New Jersey) supply both domestic demand and export markets across Latin America, Europe, and Asia-Pacific. The U.S. accounts for roughly 38% of global rapid diagnostics consumption by value, absorbing approximately USD 8.6 billion in 2024. Domestic manufacturers export an estimated USD 2.1 billion annually in rapid test kits and analyzers, with Germany, Japan, and Brazil representing the top three destination markets by volume.

Despite its manufacturing strength, the U.S. rapid diagnostics sector carries significant upstream import dependency. Nitrocellulose membranes — the functional substrate in lateral flow assays — are sourced predominantly from Sartorius (Germany) and Cytiva (U.K.). Monoclonal antibodies used in immunoassay rapid tests are partly imported from Chinese and European contract manufacturers. The COVID-19 pandemic exposed this vulnerability acutely when nitrocellulose supply constraints in 2020 delayed domestic test kit scale-up by six to eight weeks. This dual position — dominant consumer and manufacturer, yet input-dependent — defines the strategic tension shaping U.S. rapid diagnostics trade policy and investment decisions through 2032.

Growth Drivers for U.S. Rapid Diagnostics Trade and Production

Three supply chain forces are accelerating U.S. rapid diagnostics production capacity and trade volume through the forecast period. First, the PREVENT Pandemics Act and HHS strategic national stockpile replenishment programs are directing over USD 1.5 billion toward domestic manufacturing scale-up for respiratory pathogen rapid tests, directly incentivizing facility expansion by Abbott, bioMérieux, and emerging players such as Talis Biomedical. This federal procurement pull is creating baseload demand that justifies capital-intensive production investment that would otherwise be commercially marginal.

Second, the rapid expansion of urgent care and retail clinic networks — now exceeding 12,000 sites nationally — is creating distributed point-of-care testing demand that favors high-throughput rapid analyzers over send-out laboratory testing. Third, the CMS reimbursement expansion for rapid molecular diagnostics under CPT codes 87428 and 87426 has improved the economics of professional-use rapid testing, incentivizing providers to invest in on-site platforms. These combined demand-side drivers are pulling forward production capacity investment and supporting export competitiveness in Latin American and Southeast Asian markets where U.S. brands carry regulatory credibility premiums.

Supply Chain Risks and Trade Barriers

The most acute supply chain risk facing U.S. rapid diagnostics producers is concentrated sourcing of nitrocellulose membranes and specialty antibodies from a handful of European and Asian suppliers. Sartorius controls an estimated 60% of the global nitrocellulose membrane market used in lateral flow assays, creating a single-point-of-failure risk for U.S. manufacturers. Any disruption — whether from European energy cost shocks, export controls, or logistics bottlenecks at Hamburg port — propagates directly into U.S. production line stoppages within four to six weeks given current average inventory positions. No U.S.-based nitrocellulose membrane manufacturer of commercial scale currently operates, leaving this vulnerability unresolved despite policy awareness.

Trade barriers present a secondary but growing constraint. U.S. rapid diagnostics exporters face EU IVDR (In Vitro Diagnostic Regulation) compliance costs that add 18–24 months to new product registration timelines in Europe, limiting the export window for novel U.S.-developed platforms. Retaliatory tariff risk under Section 301 proceedings affects Chinese-sourced raw materials used in rapid test manufacturing, adding 7.5–25% cost uplift on key inputs including plastic substrates and conjugate pads. Currency volatility between the U.S. dollar and emerging market currencies further compresses export margins in Latin American and African distributor channels, which are price-sensitive and margin-thin.

Trade and Investment Opportunities in the U.S. Rapid Diagnostics Market

The most commercially significant trade opportunity lies in import substitution for upstream rapid diagnostics inputs. A domestic nitrocellulose membrane producer serving U.S. lateral flow manufacturers would immediately capture demand from Abbott, Quidel, and OraSure — companies that collectively consume an estimated 800 million membrane strips annually. Federal funding through BARDA's DRIVe initiative is explicitly available for this infrastructure gap, and first-mover advantage for a domestic membrane manufacturer is substantial given the long qualification timelines required by diagnostic OEMs before switching suppliers.

On the export side, U.S. rapid diagnostics manufacturers hold a strong competitive position in Latin America, particularly Brazil, Mexico, and Colombia, where regulatory frameworks recognize FDA 510(k) clearance as an expedited pathway to market approval. The Pan American Health Organization's regional procurement programs provide a structured channel for U.S. manufacturers to supply public health rapid testing programs at volume. Inbound foreign direct investment opportunities exist in U.S. contract manufacturing organizations — companies such as SEKISUI Diagnostics (Japanese-owned) and Micropoint Biosciences are already leveraging U.S. manufacturing credibility to serve global OEM customers, a model that can attract additional Asian capital into U.S. rapid diagnostics production infrastructure.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Roche Diagnostics
• bioMérieux
• Becton Dickinson
• Quidel Corporation (QuidelOrtho)
• Siemens Healthineers
• OraSure Technologies
• SEKISUI Diagnostics
• Luminex Corporation
• Cepheid (Danaher)

Regulatory and Trade Policy Environment

The U.S. rapid diagnostics trade framework is anchored by FDA's 510(k) and De Novo clearance pathways under 21 CFR Part 809, which govern in vitro diagnostic devices. Emergency Use Authorization (EUA) authority — deployed extensively during COVID-19 — remains a standing tool that can accelerate market entry during declared public health emergencies, but EUA products face mandatory de-authorization or 510(k) transition within 180 days of emergency termination. This creates trade policy uncertainty for manufacturers who scaled production under EUA and now face full regulatory compliance costs. The FDA's CLIA waiver process under the Clinical Laboratory Improvement Amendments additionally governs which rapid tests can be performed outside certified laboratory settings, directly affecting point-of-care deployment economics.

On trade policy, the U.S.-Mexico-Canada Agreement (USMCA) provides tariff-free movement of diagnostic products between the three countries, making Mexico an increasingly attractive low-cost assembly location for U.S. rapid diagnostic kit manufacturers. Section 232 and Section 301 tariffs on Chinese goods apply to selected diagnostic inputs, and ongoing trade negotiations have not resolved the antibody and substrate cost pressures these tariffs impose. The Inflation Reduction Act's domestic content provisions do not directly apply to diagnostics, but HHS procurement preferences for domestically manufactured medical countermeasures — formalized in Executive Order 14001 — create a de facto domestic content requirement for federally purchased rapid diagnostics, reshaping sourcing decisions for all major suppliers.

U.S. Rapid Diagnostics Supply Chain Outlook to 2032

The U.S. rapid diagnostics supply chain will undergo meaningful structural change between 2025 and 2032, driven by two forces: nearshoring of upstream inputs and the technological transition from immunoassay to molecular rapid formats. Federal investment through BARDA and ASPR will catalyze at least two new domestic nitrocellulose membrane or conjugate manufacturing facilities by 2028, partially reducing the European import dependency that currently represents the sector's primary single-source risk. Abbott's continued platform investment in ID NOW and Roche's expansion of its cobas Liat installed base will accelerate the displacement of lateral flow formats in professional settings, shifting competitive dynamics toward reagent-as-a-service revenue models that lock in clinical accounts for five- to seven-year cycles.

Export trade flows from the U.S. will diversify toward Sub-Saharan Africa and Southeast Asia as WHO-aligned procurement programs expand rapid diagnostics access for tuberculosis, malaria, and HIV in low- and middle-income countries. U.S. manufacturers with FDA clearance and FIND validation will carry a credibility advantage in these tenders over Chinese competitors. By 2032, the U.S. rapid diagnostics market is projected to reach USD 14.9 billion domestically, with export revenues contributing an additional USD 3.4 billion — representing a materially larger share of total manufacturer revenues than the current 20% export ratio, reflecting deliberate market expansion strategies by Abbott, Quidel, and bioMérieux into high-growth emerging markets.